Main content start
Adjunct Professor
Ying Chih Chang
Adjunct Professor
Dr. Ying Chang is the Chair of the Taiwan Science and Technology Hub and an Adjunct Professor in the Department of Chemical Engineering at Stanford University. She is also the Founder and CEO of Acrocyte Therapeutics, Inc.
Her former faculty appointments include Research Fellow (-Associate Fellow) at the Genomics Research Center, Academia Sinica, Taiwan, and Assistant Professor in the Departments of Chemical Engineering and Materials Science, and Biomedical Engineering at the University of California, Irvine. The research highlights include integrating nanomaterials, microfluidics, and bioreactors to control cell fates for tissue engineering, as well as developing circulating tumor cell 3D culture for cancer diagnostics and precision medicine. She holds multiple patents in DNA microarray constructs (assigned to Affymetrix), circulating tumor cell isolation and cancer screening (assigned to Cellmax Life Inc.), and single cell derived scaffold free 3D culture platform RCE and circulating tumor cell liquid biopsy drug test (assigned to Acrocyte Therapeutics Inc. www.acrocyte.com).
Dr. Chang’s work was recognized by the Young Investigator Award from the Whitaker Foundation, FDA breakthrough device designation for pre-cancer and cancer detection (2021), Future Tech Award (2021), 18th National Innovation Award, Taiwan (2021), and Finalist at Startup Stadium at BIO 2024, among other. She is also on the board of trustees of Kaohsiaung Medical University, and Chang Chau-Ting Memorial Foundation, a non-profit organization for science education and awareness in Taiwan. She received her BS from National Taiwan University, and PhD from Stanford University, both in Chemical Engineering.
Her former faculty appointments include Research Fellow (-Associate Fellow) at the Genomics Research Center, Academia Sinica, Taiwan, and Assistant Professor in the Departments of Chemical Engineering and Materials Science, and Biomedical Engineering at the University of California, Irvine. The research highlights include integrating nanomaterials, microfluidics, and bioreactors to control cell fates for tissue engineering, as well as developing circulating tumor cell 3D culture for cancer diagnostics and precision medicine. She holds multiple patents in DNA microarray constructs (assigned to Affymetrix), circulating tumor cell isolation and cancer screening (assigned to Cellmax Life Inc.), and single cell derived scaffold free 3D culture platform RCE and circulating tumor cell liquid biopsy drug test (assigned to Acrocyte Therapeutics Inc. www.acrocyte.com).
Dr. Chang’s work was recognized by the Young Investigator Award from the Whitaker Foundation, FDA breakthrough device designation for pre-cancer and cancer detection (2021), Future Tech Award (2021), 18th National Innovation Award, Taiwan (2021), and Finalist at Startup Stadium at BIO 2024, among other. She is also on the board of trustees of Kaohsiaung Medical University, and Chang Chau-Ting Memorial Foundation, a non-profit organization for science education and awareness in Taiwan. She received her BS from National Taiwan University, and PhD from Stanford University, both in Chemical Engineering.
Education
BS, National Taiwan University
PhD, Stanford University, Chemical Engineering
Contact
Mail Code
4300